This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, D. W. Articles by McConkey, D. J. Search for Related Content PubMed PubMed Citation Articles by Davis, D. W. Articles by McConkey, D. J.

Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors

¹Departments of Cancer Biology,² Biostatistics,³ Thoracic/Head and Neck Medical Oncology,⁴ Radiation Oncology, and⁵ Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and⁶ Department of Diagnostic Imaging, The University of Texas-Houston Health Science Center, Houston, Texas

ABSTRACT

Purpose: In a recent study, we presented preliminary evidence for biological activity in a Phase I dose-finding study (15–600 mg/m²) of recombinant human endostatin in patients with refractory solid tumors. Here, we conducted additional biomarker analyses to correlate changes in tumor biology with dose.

Experimental Design: Excisional tumor biopsies were obtained at baseline and after 56 days of endostatin therapy. Laser scanning cytometry (LSC) was used to quantify biomarker levels in whole tissue sections. Apoptosis in tumor cells (TCs) and tumor-associated endothelial cells (ECs) was quantified by fluorescent three-color anti-CD31/terminal deoxynucleotidyl transferase-mediated nick end labeling staining. Microvessel densities were measured by LSC-guided vessel contouring. Levels of tumor-associated EC BCL-2 and hypoxia-inducible factor 1 were determined by immunofluorescence and LSC quantification. The results, including tumor blood flow measured by positron emission tomography, were analyzed using a quadratic polynomial model.

Results: Significant increases in EC death and decreases in tumor microvessel density were observed, with maximal effects of endostatin at a dose of 249 mg/m² (95% confidence interval, 159–338) and 257 mg/m² (95% confidence interval, 183–331), respectively. In contrast, levels of TC death were uniformly low and did not correlate with endostatin dose. Maximal nuclear hypoxia-inducible factor 1 and minimal EC Bcl-2 levels were observed at 250 mg/m², although the changes did not reach statistical significance.

Conclusions: The data suggest that endostatin had optimal biological activity at doses 250 mg/m² in our cohort of patients. Endostatin’s failure to induce high levels of TC death may explain its lack of significant clinical activity in this Phase I trial.

This article has been cited by other articles:

				A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, et al. Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor Clin. Cancer Res., May 1, 2007; 13(9): 2643 - 2650. [Abstract] [Full Text] [PDF]

				I. Celik, O. Surucu, C. Dietz, J. V. Heymach, J. Force, I. Hoschele, C. M. Becker, J. Folkman, and O. Kisker Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve Cancer Res., December 1, 2005; 65(23): 11044 - 11050. [Abstract] [Full Text] [PDF]

				A. J. Berger, D. W. Davis, C. Tellez, V. G. Prieto, J. E. Gershenwald, M. M. Johnson, D. L. Rimm, and M. Bar-Eli Automated Quantitative Analysis of Activator Protein-2{alpha} Subcellular Expression in Melanoma Tissue Microarrays Correlates with Survival Prediction Cancer Res., December 1, 2005; 65(23): 11185 - 11192. [Abstract] [Full Text] [PDF]

				P. Nyberg, L. Xie, and R. Kalluri Endogenous Inhibitors of Angiogenesis Cancer Res., May 15, 2005; 65(10): 3967 - 3979. [Abstract] [Full Text] [PDF]

				D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al. Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668 Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689. [Abstract] [Full Text] [PDF]

				D. W. Davis, K. Inoue, C. P. N. Dinney, D. J. Hicklin, J. L. Abbruzzese, and D. J. McConkey Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts Cancer Res., July 1, 2004; 64(13): 4601 - 4610. [Abstract] [Full Text] [PDF]